RxDoctor Payments Data

Carol Johnston, MD

Ophthalmology · Jacksonville, NCNPI 1033136551

Payments from drug & device makers

$1,482in general payments, 2019–2025

Across 64 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$329
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$229
  • Sun Pharmaceutical Industries Inc.$207
  • Carl Zeiss Meditec, Inc.$134
  • Bausch & Lomb Americas Inc.$96
  • AbbVie$88
  • plus $400 from 12 others

What the payments were for

  • Food & beverage$1,482100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,482 in reported general payments places this provider in the 45th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$485,960
Medicare patients
1,137
Services billed
9,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine98$119,667
CombiganBrimonidine Tartrate/Timolol40$16,012
LumiganBimatoprost19$11,414
IlevroNepafenac27$10,256
Prednisolone Acetate165$5,196
Cyclosporine13$4,801
Latanoprost242$3,969
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$2,763
MoxifloxacinMoxifloxacin Hcl76$2,659
Fluorometholone29$2,645
Timolol Maleate200$2,380
Ketorolac Tromethamine33$1,481
Brimonidine Tartrate78$783
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$468
ErythromycinErythromycin Base35$359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$88$147,093157 claims
NovartisIlevro$18$10,25627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Jacksonville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →